Inhibitors and vaccines targeting classical immune checkpoint molecules in the TME, such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), have achieved remarkable progress in several types of cancers (Wang et al., 2019; Andrews et al., 2021). The gene discussed is CTLA4; the disease is cancer.